Brown: Risk Weighti...
Health Care: Drugs
CV Therapeutics Inc. (CVTX: NASDAQ)
$20.01 0.03 | 0.15%
04/17/09 - 04:00 PM ET
828.33K / 2.45M
Vol / Avg. Vol:20.00 / 19.98
Open / Prev. Close:19.98 - 20.01
Today's Range:7.06 - 21.15
52 Wk Range:117.26%
Performance YTD:TheStreet Rating:
Portfolios with CVTX
- Portfolio NameUser Type
- UserCramer's Take on Top Search...
- ContributorCramer's 7 Positive SignsTh...
- ContributorCramer's High-Growth Pharma...
- UserBehind The Headlines 2/26/09
- UserRAPTOR SPRTD SMALL BIOTECH ...
- UserPART 1 JPMorgan 27th Annual...
- UserHome
- Useritsracerx-healthcare
- Userrickydevel Portfolio 1
- UserMarc's Portfolio
Latest CVTX Headlines from TheStreet
- Top Takes From RealMoney 05.08.09 | 02:05 pm
- Gilead Preview: HIV Drugs Still Focus 04.21.09 | 09:04 am
- Report: Pharma Deals In 1Q Exceed All 2008 Deals 04.20.09 | 11:04 am
- Gilead's Got to Prove It's Not a One-Trick Pony 03.31.09 | 09:03 am
- The Bonanza Calls of Biotech Select 03.31.09 | 07:03 am
- Cramer's 'Mad Money' Recap: The Scramble for Tech Stocks 03.26.09 | 09:03 pm
- 'Mad Money Lightning Round': Ring Up Verizon 03.26.09 | 07:03 pm
- Top 2009 Biotech Stocks
03.23.09 | 04:03 am - Cramer: Gilead's Friend in the FDA 03.18.09 | 11:03 am
- Health Winners and Losers: Celgene 03.16.09 | 01:03 pm
Press Releases for CVTX
Partner Headlines for CVTX
- Astellas / OSI - Financial Times 05.17.10 | 07:05 pm
- Hostile takeover taboo will be consigned to history - Financial Times 03.02.10 | 10:03 pm
- Astellas / OSI - Financial Times 03.01.10 | 08:03 pm
- Astellas in $3.5bn bid to expand role in US - Financial Times 03.01.10 | 07:03 pm
